Open Access

Computational and in vitro analyses of the antibacterial effect of the ethanolic extract of Pluchea indica L. leaves

  • Authors:
    • Dwi Kusuma Wahyuni
    • Junairiah Junairiah
    • Chery Rosyanti
    • Viol Dhea Kharisma
    • Alvi Jauharotus Syukriya
    • Cici Tya Rahmawati
    • Purkan Purkan
    • Sreeramanan Subramaniam
    • Sehanat Prasongsuk
    • Hery Purnobasuki
  • View Affiliations

  • Published online on: July 29, 2024     https://doi.org/10.3892/br.2024.1825
  • Article Number: 137
  • Copyright: © Wahyuni et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The most common gram-negative, Escherichia coli, and gram-positive bacteria, Bacillus spp., have evolved different mechanisms that have caused the emergence of multi-drug resistance. As a result, drugs that block the bacterial growth cycle are needed. Here, in silico and in vitro studies were performed to assess compounds in the Pluchea indica leaf extract, a medicinal plant, that can inhibit bacterial proteins. Briefly, P. indica leaves were extracted using ethanol. The crude extract was then subjected to gas chromatography-mass spectrometry for metabolite screening. Molecular docking simulations with rhomboid protease (Rpro) (Protein data bank ID number: 3ZMI from E. coli and filamenting temperature-sensitive mutant Z (FtsZ) protein data bank ID number: 2VAM from Bacillus subtilis were performed. Moreover, the well diffusion method was used to confirm the antibacterial activity of P. indica leaf extract. A total of 10 compounds were identified in the P. indica extract and used for computational analysis. Based on drug-likeness prediction, P. indica compounds may be drug-like molecules. Binding affinity tests indicated that 10,10-Dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol and 11,11-Dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol had the most negative values. Accordingly, these compounds may be potential ligands that bind to bacterial proteins. The root mean square fluctuation values was <2 Å, indicating stable fluctuation binding for the ligand-protein complex. According to in vitro antibacterial assays, a high concentration (50%) of the P. indica extract markedly inhibited E. coli and B. subtilis, with inhibitory zone diameters of 31.86±1.63 and 21.09±0.09 mm, respectively. Overall, the compounds in the P. indica leaf extract were identified as functional inhibitors of E. coli and B. subtilis proteins via in silico analysis. This may facilitate development of antibacterial agents.

Introduction

Humans are surrounded by microorganisms, such as bacteria, fungi, protozoa, parasites and viruses (1,2). Commensal bacterial flora, such as Escherichia coli, also reside in the human digestive system; however, the spread of this bacteria to other body parts, including the bloodstream, induces pathogenicity (3,4), which ultimately causes pathogenic infections.

Pathogenic microorganisms invade living organisms with rapid self-division and acquire adaptability in new environments, including the human body, and cause contagious diseases. Antibiotics have been used worldwide to cure bacterial infections (2,5). However, bacteria can evade antibiotics via mutations, leading to resistance (6).

Commercial antibiotics are a major risk factor for antimicrobial resistance (AMR) due to overused and other reason was microorganism mutations has taken place spontaneously (7). Other associated external factors contribute to AMR, such as overcrowded living conditions and the consumption of livestock treated with antibiotics (3,4). Most external infections that occur due to Bacillus spp. are known as food poisoning (8).

The development of new antibacterial agents can address the AMR crisis (5). However, antimicrobial consumption must first be monitored as prolonged use may trigger the occurrence of AMR (9). The discovery of novel antibacterial agents from natural products, particularly plants, must be sustained. Many reports on plant-derived compounds serve as a basis for new drug development (1,10). Notably, the use of whole herbs induces an enhanced effect compared with single compounds; for example the combination compounds of Ziziphus jujuba polysaccharide and ginger 6-gingerol has synergistic effect on antioxidant and anticancer, than their dose alone (11,12).

Pluchea indica (L.) Less from the Asteraceae family is a native Indonesian plant also found in India and Thailand (13,14). P. indica exerts beneficial effects, including antidiabetic (14), antifungal (15), anti-Mycobacterium tuberculosis (16), antimicrobial (17) and wound healing (18) effects. In the present study, a computational pharmacology network analysis was performed with molecular docking of P. indica compounds as potential antibacterial agents against E. coli and B. subtilis. The present study aimed to highlight promising compounds in the ethanolic extract of P. indica that can be explored in drug discovery.

Materials and methods

Plant collection and identification

Dry P. indica was obtained from the Medicinal Plant Garden (Surabaya, Indonesia) and validated at the Plant Systematic Laboratory (Universitas Airlangga, Surabaya, Indonesia). A voucher specimen was deposited at the Plant Systematic Laboratory (no. PI0126012024).

Extraction

The leaves of P. indica were air-dried, ground into a powder (20 mesh size) and macerated in absolute ethanol (Pro Analysis; Merck KGaA) at a ratio of 1:10. The maceration process was performed at room temperature (28±2˚C) for 24 h. The extracted products were filtered using a filter paper, evaporated using a rotary evaporator at 60˚C, weighed to determine the yield and stored at 4˚C, as previously described (19).

Compound profiling via gas chromatography-mass spectrophotometry (GC-MS)

Compound profiles of ethanolic extracts of P. indica leaves were determined using GC-MS. GC-MS analysis was performed using an Agilent GC-MSD (Agilent Technologies Deutschland GmbH; cat. no. 19091S-433UI) equipped with a capillary column (30.00 m x 250.00 µm x 0.25 µm) and a mass detector in electron impact mode with full scan (50,550 atomic mass unit). Helium was used as the carrier gas at a flow rate of 3 ml/min (total flow rate, 14 ml/min). The injector temperature was 280˚C and the oven temperature ranged from 60 to 250˚C. Peaks in the chromatograms were identified using the mass spectra. Chemicals were identified by comparing mass spectra to those in a Standard Reference Database (version 02. L, National Institute of Standards and Technology). Components with quality scores >80% were selected. The relative proportion of each component was estimated from the overall peak area in the chromatograph, as previously described (20).

In silico pathway analysis of antimicrobial compounds. Sample retrieval

The following compounds were collected via GC-MS: Limonene oxide, cis-, ethyltetramethylcyclopentadiene; hexadecanoic acid, methyl ester; 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol; 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0) undecan-3-ol; 8,11-octadecadienoic acid, methyl ester; 9,12,15-octadecatrienoic acid, methyl ester; phytol; silane, [(methylsilyl)methyl](silylmethyl)- and n-hexadecanoic acid. PubChem database (pubchem.ncbi.nlm.nih.gov/) was used to retrieve the compound ID number (CID), simplified molecular input line entry system (SMILE) Canonical and 3D files in sdf format for the ligands (21). The Protein Data Bank (PDB) file was input in Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) database (rcsb.org/) for target preparation, which involved B. subtilis-Filamenting temperature-sensitive mutant Z (FtsZ) (Z ring) and E. coli-Rhomboid protease (Rpro). Water molecules and native ligands on targets were removed using PyMOL software v.2.5.2 (Schrödinger, Inc.) under an academic license (21,22).

Drug-likeness prediction. Compounds were assessed as drug-like molecules by referring to drug-likeness rules, such as Lipinski (23), Ghose (24), Veber (25), Egan (26) and Muegge (27). Bioavailability score was used to identify the ability of candidate drug molecules to circulate in the body. Drug-likeness analysis was performed using SwissADME (swissadme.ch/) (20,28).

Ligand-protein docking. The binding activity of the ligand to the target and the interaction pattern were identified using molecular docking. Docking was performed to determine the antibacterial potential and inhibitor mechanism between P. indica compounds and targets. Of note, the grid covered the entire surface of the target. In addition, the docking grid consisted of FtsZ: Center(Å) X:28.189 Y: -7.627 Z: -4.629 dimensions (Å) X: 26.235 Y: 21.066 Z: 29.239 & Rpro: Center (Å) X:15.407 Y: -11.974 Z: 43.963 dimensions (Å) X: 28.085 Y: 21.013 Z: 38.783. The docking simulation was performed using PyRx 0.9.9 software (Scripps Research) under an academic license (29,30).

Chemical interaction. The molecular interactions between the molecular complexes from docking simulation were identified using Discovery Studio Visualizer v.16.1 (Dassault Systèmes SE). Weak bond interactions, such as van der Waals, hydrogen, hydrophobic, π-alkyl, and electrostatic interactions, were formed in the ligand-protein complex. These interactions contribute to initiation of an inhibitory response of the ligand toward specific target domains (31).

Molecular dynamic simulation

Molecular stability analysis or docking validation was conducted using molecular dynamics simulations in CABS-flex-2 (biocomp.chem.uw.edu.pl/CABSflex2). Molecular stability was displayed using a root mean square fluctuation (RMSF) graph. To achieve molecular stability, the protein-ligand complex must have RMSF value <3 Å (32,33).

Antimicrobial activity assessment. Media and inoculum preparation

Two bacterial strains, B. subtilis (cat. no. 1248) was purchased from Thailand Institute of Scientific and Technology Research and E. coli (cat. no. 25922) was purchased from The American Type Culture Collection, were tested using antimicrobial assays. Solid and liquid media were used to conduct antimicrobial experiments and maintain bacterial cultures. Nutrient agar (NA; Merck, Germany) was used as the solid medium to test antibacterial activity. NA was used in the reaction tubes to maintain the microbial culture. Nutrient broth (NB, Merck, Germany) was employed as liquid media for bacterial strain subcultures and precultures. The bacterial strains were pre-cultured in culture bottles containing sterile NB in a 37˚C incubator for 24 h, then diluted to 10% cultures before inoculation. The absorbance of the 10% bacterial culture was adjusted with sterile water using a spectrophotometer to meet the 0.5 McFarland standard (19).

Well diffusion assay. Well diffusion assay was performed to determine the antimicrobial activity based on diameter of the inhibitory zone (DIZ) on the surface of NA. A total of 10 ml NA was placed in a sterile Petri dish and allowed to harden. Thereafter, 30 ml NA was added. Following cooling (25±2˚C) of the second layer, 1 ml bacterial culture was added to the NA and the second layer was allowed to completely solidify. A total of four wells was created on the second layer of the film for samples and controls. Extracts diluted in 10% DMSO (250 and 500 mg/ml) served as the samples, 10% DMSO served as the negative control and chloramphenicol (1000 µg/ml) served as the positive control. Each well received 10 µl diluted samples; four replicates were prepared. The plates were incubated at 37˚C for 24 h. DIZ was measured using Vernier calipers and the mean was calculated and compared with that of the positive control, as previously described (20). The percentage of inhibition (PI) was calculated as follows: PI (%)=mean DIZ of the extract/DIZ of positive control x 100% (1). The antimicrobial data were obtained from three independent experiments and are expressed as the mean ± standard deviation.

Results

Extraction product and compound identification

The ethanolic extraction of P. indica dried leaves yielded ~17.79% crude extract from 88.8 g raw material (dried leaves). A total of 12 compounds, was identified via GC-MS. (Table I). Hexadecanoic acid methyl ester, 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol, phytol, silane and n-hexadecanoic acid had a quality score >80% and higher peak area than other compounds identified via GC-MS (Fig. 1).

Table I

GC-MS analysis of Pluchea indica ethanolic extract.

Table I

GC-MS analysis of Pluchea indica ethanolic extract.

PeakRTCompoundMolecular formulaMolecular weight, g/molChromatogram peak area, %
131.468Limonene oxide, cis- C10H16O152.232.34
232.670 Ethyltetramethylcyclopentadiene C11H18150.261.32
335.541Hexadecanoic acid, methyl ester C17H34O2270.453.88
437.221 10,10-Dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol C15H24O220.351.83
537.313 11,11-Dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol C15H24O220.354.70
640.399 8,11-Octadecadienoic acid, methylester C19H34O2294.502.44
741.527 9,12,15-Octadecatrienoic acid, methyl ester C19H32O2292.503.82
842.213Phytol C20H40O296.539.33
945.147Silane, [(methylsilyl)methyl](silylmethyl)- C3H7Si3127.343.36
1046.857n-Hexadecanoic acid C16H32O2256.4227.36

[i] RT, retention time.

Computational analysis using molecular docking

The compounds were confirmed using CID, with information on canonical SMILE and 2-dimentional (2D) structures from the PubChem (Table II). Two targets, FtsZ from B. subtilis and Rpro protein from E. coli, were employed (Fig. 2). Before compound processing with the target via molecular docking, all compounds were checked for drug-likeness to assess similarity to an existing drug. Rules, such as Lipinski's Rule of Five (Ro5), Ghose, Veber, Egan and Muegge, were also applied. Notably, all compounds in the P. indica extract were predicted to be drug-like molecules with a bioavailability score of 0.55, except n-hexadecanoic acid (Table III).

Table III

Pluchea indica compounds predicted as drug-like molecules.

Table III

Pluchea indica compounds predicted as drug-like molecules.

CompoundLipinskiGhoseVeberEganMueggeBioavailability score
Limonene oxide, cis-PassFailPassPassFail0.55
EthyltetramethylcyclopentadienePassFailPassPassFail0.55
Hexadecanoic acid, methyl esterPassFailFailPassFail0.55
10,10-Dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-olPassPassPassPassFail0.55
11,11-Dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-olPassPassPassPassFail0.55
8,11-Octadecadienoic acid, methyl esterPassFailFailFailFail0.55
9,12,15-Octadecatrienoic acid, methyl esterPassFailFailPassFail0.55
PhytolPassFailFailFailFail0.55
Silane, [(methylsilyl)methyl](silylmethyl)-PassFailPassPassFail0.55
n-Hexadecanoic acidPassPassFailPassFail0.85

Interactions of targets from bacterial proteins and ligands from all P. indica compounds were subjected to computational analysis using molecular docking. P. indica compounds with the most negative binding affinities were 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol and 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol (both-6.0 kcal/mol) on FtsZ (PDB ID: 2VAM) for B. subtilis and 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.beta.-ol on Rpro (PDB ID: 3ZMI) for E. coli (-7.8 kcal/mol; Table IV). Molecular interaction between targeted proteins and the pocket-binding domain of ligands from P. indica was performed and visualized as 3D structure. Compounds with the most negative binding affinities were 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol and 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol (Fig. 2). The analysis also revealed that the ligands formed weak bonds, such as van der Waals and π-alkyl bonds for 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol, on FtsZ-B. subtilis and Rpro-E. coli. For 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol, the weak bonds were van der Waals, hydrogen and alkyl bonds in FtsZ-B. subtilis (Fig. 3; Table V).

Table IV

Binding affinity from the docking analysis.

Table IV

Binding affinity from the docking analysis.

 Binding affinity, kcal/mol
CompoundBacillus subtilis (FtsZ PDB ID: 2VAM)Escherichia coli (Rpro PDB ID: 3ZMI)
Limonene oxide, cis--5.8-6.8
Ethyltetramethylcyclopentadiene-5.4-6.3
Hexadecanoic acid, methyl ester-4.9-5.8
10,10-Dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol-6.0-7.8
11,11-Dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol-6.0-7.2
8,11-Octadecadienoic acid, methyl ester-4.8-5.6
9,12,15-Octadecatrienoic acid, methyl ester-4.7-6.1
Phytol-4.7-6.1
n-Hexadecanoic acid-5.0-5.5
Silane, [(methylsilyl)methyl](silylmethyl)--4.5-5.0

Table V

Molecular interaction and dynamic analysis of antimicrobial candidate compounds

Table V

Molecular interaction and dynamic analysis of antimicrobial candidate compounds

 RMSF, Å
CompoundTargetLigand interaction domainBinding siteMean value of amino acid residues
10,10-Dimethyl-2,6-dimethylenebicyclo (7.2.0)undecan-5.β.-olFtsZ PDB ID: 2VAM (B. subtilis)van der Waals: Asn25, Asp187, Gly22, Gly21, Arg143, Gly104, Gly107, Met105, Glu139, Asn166, Thr133 π-alkyl: Phe183, Pro135van der Waals: 0.517, 0.423, 0.390, 0.198, 0.730, 0.292, 1.251, 0.760, 1.295, 0.513, 0.281 π-alkyl: 0.688, 0.5640.608
 Rpro PDB ID: 3ZMI (E. coli)van der Waals: Ser201, Asn154, Phe153, His150, Gly240, Ala239 π-alkyl: Val204, Trp157, His254, Trp236, Tyr205, Met149van der Waals: 0.142, 0.384, 0.238, 1.014, 0.726, 0.897 π-alkyl: 0.726, 0.352, 0.343, 0.623, 0.116, 0.6400.157
11,11-Dimethyl-4,8-dimethylenebicyclo (7.2.0)undecan-3-olFtsZ PDB ID: 2VAM (B. subtilis)van der Waals: Glu34, Asp199, Val35, Thr203, Gln36, Ile298, Asn301, Gln195 Hydrogen: Asn299, Glu300 Alkyl: Val297van der Waals: 1.323, 1.180, 0.912, 1.462, 1.107, 0.707, 2.226, 0.099 Hydrogen: 0.964, 1.615 Alkyl: 0.4491.095

[i] B. subtilis, Bacillus subtilis; E. coli, Escherichia coli; FtsZ, filamenting temperature-sensitive mutant Z; Rpro, Rhomboid protease.

To determine the stability of protein-ligand binding, docking validation was performed via molecular dynamics simulation by referring to the RMSF value. The RMSF values from binding site on ligand interaction domains were <2 Å, indicating stability. The RMSF value was 0.608 Å for the 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol_FtsZ complex, 0.157 Å for the 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol_FtsZ complex, and 1.095 Å for the 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol_Rpro complex (Table V). The molecular interactions were due to van der Waals (Asn25, Asp187, Gly22, Gly21, Arg143, Gly104, Gly107, Met105, Glu139, Asn166, Thr133) and π-alkyl bonds (Phe183, Pro135) in the 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β-ol_FtsZ complex; van der Waals bonds (Ser201, Asn154, Phe153, His150, Gly240, Ala239) and π-alkyl bonds (Val204, Trp157, His254, Trp236, Tyr205, Met149) in the 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol_FtsZ complex and van der Waals (Glu34, Asp199, Val35, Thr203, Gln36, Ile298, Asn301, and Gln195), hydrogen (Asn299 and Glu300) and alkyl bonds (Val297) in the 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β-ol_Rpro complex (Fig. 3). Fig. 4 shows the structural fluctuations and RMSF graph of the target protein.

In vitro antibacterial activity based on well diffusion assay

The antibacterial activity of P. indica extract was determined using the well diffusion method. Notably, 50% P. indica extract exhibited the strongest inhibitory activity against E. coli growth (DIZ, 31.86±1.63 mm), with PI >80% that of the positive control (chloramphenicol). Moreover, 25% extract exhibited strong inhibitory activity (DIZ, 21.29±1.02 mm), with PI >~50% (Table VI). The 50% extract caused a larger DIZ than the 25% extract against B. subtilis, with PI >40% at both concentrations compared with that of the positive control (Fig. 5). Therefore, the higher the concentration of the extract, the greater the antibacterial activity.

Table VI

Well diffusion of Pluchea indica ethanolic extract.

Table VI

Well diffusion of Pluchea indica ethanolic extract.

 DIZ, mmPI, %
GroupE. coliB. subtilisE. coliB. subtilis
25% extract21.29±1.0217.76±1.2355.6044.53
50% extract31.86±1.6321.09±0.0982.1350.74
Chloramphenicol38.79±0.4339.88±0.32100.00100.00

[i] E. coli, Escherichia coli; B. subtilis, Bacillus subtilis; DIZ, diameter of the inhibitory zone; PI, percentage inhibition.

Discussion

To the best of our knowledge, novel drugs from plant-derived compounds have not been developed recently. The field of ethnopharmacology, which involves use traditional medicinal plants, can be applied in modern medical practice as therapeutic agent (34,35). P. indica was used as an antibacterial agent in the present study. Various factors, including solvents, can affect the proportion of bioactive compounds in an extract (36,37). In the present study, P. indica was extracted with ethanol, a universal solvent, to obtain bioactive compounds with antibacterial properties. Ethanol extract of P. indica is an antibacterial agent against B. cereus, E. coli, Pseudomonas fluorescens, Staphylococcus aureus and Salmonella typhimurium (38).

In the present study, E. coli was employed as a representative gram-negative bacterium that commonly causes infection when it occupies the gastrointestinal and urinary systems, leading to individuals becoming immunocompromised (1,39). Gram-positive bacteria, including Bacillus spp., are commonly detected in the blood, stool and respiratory systems of infected patients (8). One of the 29 strains of B. subtilis was previously identified as MDR, with high resistance to norfloxacin (40).

Plant-derived compounds have gained popularity in drug development owing to minimal side effects on human health (41). Phytochemicals in P. indica extract have been demonstrated to exhibit notable wound-healing activity (18) and anti-venom potential (42). Recently, to accelerate drug discovery, conventional methods, such as high-throughput screening (HTS) and virtual HTS, have been developed (16). HTS frequently produces bulky hydrophobic metabolites that are poorly suited to chemical alterations (16). Thus, in silico docking studies are a bioinformatics tool to define the binding form and binding affinity score (43).

The principal mechanism of docking involves identifying plant metabolites as candidates for drug improvement via binding to the protein target of a cell (16,43,44). In the present study, computational analysis using docking simulations required bacterial protein targets. Several subcellular protein targets are present in B. subtilis and E. coli, including Murein cluster e-B protein (MreB), MreC, The partitioning motor protein (ParM), Z-associated protein D (ZapD) and FtsZ (45). MreB and MreC localize in a helical pattern along the longitudinal axis of the entire cell (46,47), ParM is present in intercellular filaments along the cell length (48) and ZapD is focally localized to the mid-cell of the septum in an FtsZ-dependent manner (49).

FtsZ protein plays a crucial role in bacterial division and is arranged in a large protein complex in the middle of dividing cells called divisomes (50). As the regulation and function of the divisome are dependent on FtsZ, this protein is the first to be recruited for division (51). Inhibition of FtsZ may be a promising approach to combat antibiotic resistance. FtsZ is conserved in most bacteria but absent in eukaryote cells. The structures of FtsZ protein are available in the PDB (ID numbers, such as PDB ID: 2VXY, 3VPA, 4DXD, 5H5G) and ID 2VAM, which identified the FtsZ protein from B. subtilis as the protein target in this present study (51). Rpro is an intramembrane protease implicated in critical regulation of different cellular signaling processes (52,53). Thus, the inhibition of these bacterial proteins inhibits growth (52).

Computational approaches to drug discovery have led to the development of alternative tools to decrease costs and determine the effectiveness of potential drug candidates. Computational screening from ligand-based sources has been performed to identify potential compound inhibitors for drug repurposing (16,43). However, information such as CID, (SMILE) Canonical and 3D files about the candidate ligands must first be obtained. The present study revealed 10 compounds in the P. indica leaf extract using GC-MS screening.

Drug-likeness analysis can assist in increasing probability of a natural chemical progressing through clinical trials (54). The present study used Lipinski's Ro5, Ghose, Veber and Muegge. Ro5 assesses lipophilicity (LogP), molecular mass, hydrogen bonding and molar refractivity (55). Veber measures oral bioavailability based on molecular weight, topological surface area and hydrogen and rotatable bonds. Ghose evaluates drug likeness using LogP, refractivity and the number of atoms. Muegge evaluation predicts drug-likeness using drug databases and pharmacophore calculations (56,57). Two compounds, 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.beta.-ol and 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol, passed four (Lipinski, Ghose, Veber, and Egan) of these rules. In this analysis, a compound must pass at least one rule to proceed to the next step in the molecular docking and dynamic simulation. Implementation of drug-likeness rules improves physicochemical and pharmacokinetic profiles of active substances (58,59).

The Veber's rule-based bioavailability score, which indicates the capacity for absorption and circulation, determines the pharmacokinetic profile of drug-like molecules. Here, the best performance indicator of antibacterial drug effectiveness against target microorganisms, such as E. coli and B. subtilis, had a bioavailability score of 0.55 (60,61).

Ligands form interaction patterns or pocket-binding regions on weakly bonded targets. The binding affinity is the binding energy of the ligand during its interaction with the target. According to Gibbs' rule, a lower binding affinity value indicates increased ligand activity, which means the compound with the most negative value is the predicted ligand (62,63).

Candidate antimicrobial agents with inhibitory activity should have a lower (the most negative) binding affinity (64-66). Based on docking simulation, 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol and 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol from P. indica may be antimicrobial drugs with inhibitory activities against FtsZ and Rpro proteins. 10,10-Dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol is a terpenoid derivative found in the extracts of Mammea siamensis flower and young leaves (67); this compound is also one of the volatile compounds found in the Artemisia argyi fruit extract (68). 11,11-Dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol (bicyclo (7.2.0) undecan-3-ol) and 11,11-dimethyl-4,8-bis(methylene)-are volatile compounds in Achillea millefolium essential oil (69), propolis (70), and this compound in Syzygium aromaticum extract has potential as an antifungal and nematicidal (71). Notably, 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol is positively associated with antibacterial activity (72).

Further analysis revealed that these two ligands could form van der Waals, hydrogen, and π-alkyl bonds. Weak-bond interactions in protein inhibitors, serve a role in promoting biological responses such as disrupt the regulate enzyme, interfering the metabolic role and blocking or slowing enzymatic function. The existence of van der Waals, hydrogen, hydrophobic, π-alkyl, and electrostatic interactions can increase stability of ligand-protein interactions (73).

In the present study, docking validation was performed through molecular dynamics simulation of a ligand-protein complex. The molecular complexes, 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.-ol_FtsZ, 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol_FtsZ, and 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β-ol_Rpro, were identified based on their molecular stability. RMSF of molecular complexes with stable fluctuations is <3 Å (74,75).

In vitro, higher concentrations of the extract induced stronger antibacterial activity. Based on a previous study, this activity could be classified as very strong as DIZ was >15 mm (76). The compounds in the P. indica leaf extract exhibited strong antibacterial activity against gram-negative E. coli. The compounds predicted as potential antibacterial agents were 10,10-dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol and 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol. However, the present study had some limitations. The in vitro experiments must be supplemented by additional analysis to confirm that the compounds have effective activity against the protein target. The in silico approach requires more extensive protein screening to ensure compounds affect bacterial cells. The present study excluded the non-proteins analysis and only focus on essential bacterial proteins, such as bacterial proteins that serve key role in division and growth (Rpro and FtsZ). The present study only compared the compounds in the extract and excluded the positive control in molecular docking analysis to reduce false positive and to improve reliability and efficiency as previously described (77,78).

Overall, 10 compounds were identified in the P. indica leaf extract. 10,10-Dimethyl-2,6-dimethylenebicyclo(7.2.0)undecan-5.β.-ol and 11,11-dimethyl-4,8-dimethylenebicyclo(7.2.0)undecan-3-ol formed a ligand-protein complex with FtsZ from B. subtilis and Rpro from E. coli. Based on in vitro experiments, the 50% P. indica extract had the strongest inhibitory effect on the growth of E. coli and B. subtilis. Therefore, these ligands from P. indica leaf extract may serve as candidate inhibitors of targeted proteins that contribute to pathogenicity in the bacterial life cycle.

Acknowledgements

Not applicable.

Funding

Funding: The present study was supported by Universitas Airlangga (Contract no. 215/UN3.15/PT/2022).

Availability of data and materials

The data generated in the present study are included in the figures and/or tables of this article.

Authors' contributions

DKW, JJ, CR, SS, PP, SP and HP designed the study. CR, VDK, AJS and CTR performed experiments and analyzed data. DKW, VDK and AJS wrote and edited the manuscript. DKW, JJ, SS, PP, SP and HP confirm the authenticity of all the raw data and reviewed the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Periferakis A, Periferakis K, Badarau IA, Petran EM, Popa DC, Caruntu A, Costache RS, Scheau C, Caruntu C and Costache DO: Kaempferol: Antimicrobial properties, sources, clinical, and traditional applications. Int J Mol Sci. 23(15054)2022.PubMed/NCBI View Article : Google Scholar

2 

Hikmawanti NPE, Saputri FC, Yanuar A, Jantan I, Ningrum RA and Mun'im A: Insights into the anti-infective effects of Pluchea indica (L.) Less and its bioactive metabolites against various bacteria, fungi, viruses, and parasites. J Ethnopharmacol. 320(117387)2024.PubMed/NCBI View Article : Google Scholar

3 

Erb A, Stürmer T, Marre R and Brenner H: Prevalence of antibiotic resistance in Escherichia coli: Overview of geographical, temporal, and methodological variations. Eur J Clin Microbiol Infect Dis. 26:83–90. 2007.PubMed/NCBI View Article : Google Scholar

4 

Mageiros L, Méric G, Bayliss SC, Pensar J, Pascoe B, Mourkas E, Calland JK, Yahara K, Murray S, Wilkinson TS, et al: Genome evolution and the emergence of pathogenicity in avian Escherichia coli. Nat Commun. 12(765)2021.PubMed/NCBI View Article : Google Scholar

5 

World Health Organization (WHO): Antimicrobial resistance. WHO, Geneva, 2023.

6 

Martinez JL: General principles of antibiotic resistance in bacteria. Drug Discov Today Technol. 11:33–39. 2014.PubMed/NCBI View Article : Google Scholar

7 

Tang KWK, Millar BC and Moore JE: Antimicrobial resistance (AMR). Br J Biomed Sci. 80(11387)2023.PubMed/NCBI View Article : Google Scholar

8 

Kobayashi A, Higashi H, Shimada T and Suzuki S: Baseline and seasonal trends of Bacillus cereus and Bacillus subtilis from clinical samples in Japan. Infect Prev Pract. 5(100272)2023.PubMed/NCBI View Article : Google Scholar

9 

World Health Organization (WHO): Optimizing surveillance of antimicrobial consumption (AMC). WHO, Geneva, 2022.

10 

Seidel V: Plant-derived chemicals: A source of inspiration for new drugs. Plants (Basel). 9(1562)2020.PubMed/NCBI View Article : Google Scholar

11 

Wu Z, Gao R, Li H, Wang Y, Luo Y, Zou J, Zhao B and Chen S: New insight into the joint significance of dietary jujube polysaccharides and 6-gingerol in antioxidant and antitumor activities. RSC Adv. 11:33219–33234. 2021.PubMed/NCBI View Article : Google Scholar

12 

Habtemariam S: Going back to the good old days: The merit of crude plant drug mixtures in the 21st century. Int J Complement Alt Med. 6(00182)2017.

13 

Jena GSJP, Mishra R, Nayak S and Satapathy KB: Addition of five new generic asteraceous members to the flora of Odisha, India. J Indian Bot Soc. 100:53–61. 2020.

14 

Syabana MA, Yuliana ND, Batubara I and Fardiaz D: Antidiabetic activity screening and nmr profile of vegetable and spices commonly consumed in Indonesia. Food Sci Technol. 41:254–264. 2021.

15 

Demolsky WL, Sugiaman VK and Pranata N: Antifungal activity of Beluntas ‘Indian Camphorweed’(Pluchea indica) ethanol extract on Candida albicans in vitro using different solvent concentrations. Eur J Dent. 16:637–642. 2021.PubMed/NCBI View Article : Google Scholar

16 

Kumar M, Singh SK, Singh PP, Singh VK, Rai AC, Srivastava AK, Shukla L, Kesawat MS, Kumar Jaiswal A, Chung SM and Kumar A: Potential anti-Mycobacterium tuberculosis activity of plant secondary metabolites: Insight with molecular docking interactions. Antioxidants (Basel). 10(1990)2021.PubMed/NCBI View Article : Google Scholar

17 

Cadamuro RD, da Silveira Bastos IMA, Silva IT, da Cruz ACC, Robl D, Sandjo LP, Alves S Jr, Lorenzo JM, Rodríguez-Lázaro D, Treichel H, et al: Bioactive compounds from mangrove endophytic fungus and their uses for microorganism control. J Fungi (Basel). 7(455)2021.PubMed/NCBI View Article : Google Scholar

18 

Chiangnoon R, Samee W, Uttayarat P, Jittachai W, Ruksiriwanich W, Sommano SR, Athikomkulchai S and Chittasupho C: Phytochemical analysis, antioxidant, and wound healing activity of Pluchea indica L.(Less) branch extract nanoparticles. Molecules. 27(635)2022.PubMed/NCBI View Article : Google Scholar

19 

Wahyuni DK, Nariswari A, Supriyanto A, Purnobasuki A, Punnapayak H, Bankeeree W, Prasongsuk S and Ekasari W: Antioxidant, antimicrobial, and antiplasmodial activities of Sonchus arvensis L. leaf ethyl acetate fractions. Pharmacogn J. 14 (Suppl):S993–S998. 2022.

20 

Wahyuni DK, Wacharasindhu S, Bankeeree W, Punnapayak H and Prasongsuk S: In silico anti-SARS-CoV-2, antiplasmodial, antioxidant, and antimicrobial activities of crude extracts and homopterocarpin from heartwood of Pterocarpus macrocarpus Kurz. Heliyon. 9(e13644)2023.PubMed/NCBI View Article : Google Scholar

21 

Listiyani P, Kharisma VD, Ansori ANM, Widyananda MH, Probojati RT, Murtadlo AAA, Turista DDR, Ullah ME, Jakhmola V and Zainul R: In silico phytochemical compounds screening of Allium sativum targeting the Mpro of SARS-CoV-2. Pharmacogn J. 14:604–609. 2022.

22 

El Mchichi L, El Aissouq A, Kasmi R, Belhassan A, El-Mernissi R, Ouammou A, Lakhlifi T and Bouachrine M: In silico design of novel Pyrazole derivatives containing thiourea skeleton as anti-cancer agents using: 3D QSAR, drug-likeness studies, ADMET prediction and molecular docking. Mater Today Proc. 45:7661–7674. 2021.

23 

Lipinski CA, Lombardo F, Dominy BW and Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 23:3–25. 1997.PubMed/NCBI View Article : Google Scholar

24 

Ghose AK, Viswanadhan VN and Wendoloski JJ: A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem. 1:55–68. 1999.PubMed/NCBI View Article : Google Scholar

25 

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW and Kopple KD: Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 45:2615–2623. 2002.PubMed/NCBI View Article : Google Scholar

26 

Egan WJ, Merz KM Jr and Baldwin JJ: Prediction of drug absorption using multivariate statistics. J Med Chem. 43:3867–3877. 2000.PubMed/NCBI View Article : Google Scholar

27 

Muegge I, Heald SL and Brittelli D: Simple selection criteria for drug-like chemical matter. J Med Chem. 44:1841–1846. 2001.PubMed/NCBI View Article : Google Scholar

28 

Johnson TO, Adegboyega AE, Iwaloye O, Eseola OA, Plass W, Afolabi B, Rotimi D, Ahmed EI, Albrakati A, Batiha GE and Adeyemi OS: Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2. J Pharmacol Sci. 147:62–71. 2021.PubMed/NCBI View Article : Google Scholar

29 

Dibha AF, Wahyuningsih S, Ansori ANM, Kharisma VD, Widyananda MH, Parikesit AA, Sibero MT, Probojati RT, Murtadlo AAA, Trinugroho JP, et al: Utilization of secondary metabolites in algae Kappaphycus alvarezii as a breast cancer drug with a computational method. Pharmacogn J. 14:536–543. 2022.

30 

Amer HH, Eldrehmy EH, Abdel-Hafez SM, Alghamdi YS, Hassan MY and Alotaibi SH: Antibacterial and molecular docking studies of newly synthesized nucleosides and Schiff bases derived from sulfadimidines. Sci Rep. 11(17953)2021.PubMed/NCBI View Article : Google Scholar

31 

Jaszczyszyn I, Bielska W, Gawlowski T, Dudzic P, Satława T, Kończak J, Wilman W, Janusz B, Wróbel S, Chomicz D, et al: Structural modeling of antibody variable regions using deep learning-progress and perspectives on drug discovery. Front Mol Biosci. 10(1214424)2023.PubMed/NCBI View Article : Google Scholar

32 

Wijaya RM, Hafidzhah MA, Kharisma VD, Ansori ANM and Parikesit AA: Makara journal of scienc e. Makara J Sci. 162(171)2021.

33 

Peach R, Arnaudon A and Barahona M: Relative, local and global dimension in complex networks. Nat Commun. 13(3088)2022.PubMed/NCBI View Article : Google Scholar

34 

Pirintsos S, Panagiotopoulos A, Bariotakis M, Daskalakis V, Lionis C, Sourvinos G, Karakasiliotis I, Kampa M and Castanas E: From traditional ethnopharmacology to modern natural drug discovery: A methodology discussion and specific examples. Molecules. 27(4060)2022.PubMed/NCBI View Article : Google Scholar

35 

Bhagawan WS, Ekasari W and Agil M: Ethnopharmacology of medicinal plants used by the Tenggerese community in Bromo Tengger Semeru National Park, Indonesia. Biodiversitas J Biol Divers. 24:5464–5477. 2023.

36 

Moldovan ML, Iurian S, Puscas C, Silaghi-Dumitrescu R, Hanganu D, Bogdan C, Vlase L, Oniga I and Benedec D: A design of experiments strategy to enhance the recovery of polyphenolic compounds from Vitis vinifera by-products through heat reflux extraction. Biomolecules. 9(529)2019.PubMed/NCBI View Article : Google Scholar

37 

Zhang QW, Lin LG and Ye WC: Techniques for extraction and isolation of natural products: A comprehensive review. Chin Med. 13(20)2018.PubMed/NCBI View Article : Google Scholar

38 

Srimoon R and Ngiewthaisong S: Antioxidant and antibacterial activities of Indian marsh fleabane (Pluchea indica (L.) Less). KKU Res J. 20:144–154. 2015.

39 

Kaper JB, Nataro JP and Mobley HL: Pathogenic Escherichia coli. Nat Rev Microbiol. 2:123–140. 2004.

40 

Adamski P, Byczkowska-Rostkowska Z, Gajewska J, Zakrzewski AJ and Kłębukowska L: Prevalence and antibiotic resistance of Bacillus sp. isolated from raw milk. Microorganisms. 11(1065)2023.PubMed/NCBI View Article : Google Scholar

41 

Dehelean CA, Marcovici I, Soica C, Mioc M, Coricovac D, Iurciuc S, Cretu OM and Pinzaru I: Plant-derived anticancer compounds as new perspectives in drug discovery and alternative therapy. Molecules. 26(1109)2021.PubMed/NCBI View Article : Google Scholar

42 

Ibrahim SRM, Bagalagel AA, Diri RM, Noor AO, Bakhsh HT and Mohamed GA: Phytoconstituents and pharmacological activities of Indian Camphorweed (Pluchea Indica): A multi-potential medicinal plant of nutritional and ethnomedicinal importance. Molecules. 27(2383)2022.PubMed/NCBI View Article : Google Scholar

43 

Kitchen DB, Decornez H, Furr JR and Bajorath J: Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat Rev Drug Discov. 3:935–949. 2004.PubMed/NCBI View Article : Google Scholar

44 

Sandeep G, Nagasree KP, Hanisha M and Kumar MMK: AUDocker LE: A GUI for virtual screening with AUTODOCK Vina. BMC Res Notes. 4(445)2011.PubMed/NCBI View Article : Google Scholar

45 

Sharavanan VJ, Sivaramakrishnan M, Kothandan R, Muthusamy S and Kandaswamy K: Molecular docking studies of phytochemicals from Leucas aspera targeting Escherichia coli and Bacillus subtilis subcellular proteins. Pharmacogn J. 11:278–285. 2019.

46 

Domínguez-Cuevas P, Porcelli I, Daniel RA and Errington J: Differentiated roles for MreB-actin isologues and autolytic enzymes in Bacillus subtilis morphogenesis. Mol Microbiol. 89:1084–1098. 2013.PubMed/NCBI View Article : Google Scholar

47 

Leaver M and Errington J: Roles for MreC and MreD proteins in helical growth of the cylindrical cell wall in Bacillus subtilis. Mol Microbiol. 57:1196–1209. 2005.PubMed/NCBI View Article : Google Scholar

48 

Møller-Jensen J, Jensen RB, Löwe J and Gerdes K: Prokaryotic DNA segregation by an actin-like filament. EMBO J. 21:3119–3127. 2002.PubMed/NCBI View Article : Google Scholar

49 

Durand-Heredia J, Rivkin E, Fan G, Morales J and Janakiraman A: Identification of ZapD as a cell division factor that promotes the assembly of FtsZ in Escherichia coli. J Bacteriol. 194:3189–3198. 2012.PubMed/NCBI View Article : Google Scholar

50 

Du RL, Sun N, Fung YH, Zheng YY, Chen YW, Chan PH, Wong WL and Wong KY: Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism. RSC Med Chem. 13:79–89. 2021.PubMed/NCBI View Article : Google Scholar

51 

Ortiz C, Natale P, Cueto L and Vicente M: The keepers of the ring: Regulators of FtsZ assembly. FEMS Microbiol Rev. 40:57–67. 2016.PubMed/NCBI View Article : Google Scholar

52 

Tichá A, Stanchev S, Vinothkumar KR, Mikles DC, Pachl P, Began J, Škerle J, Švehlová K, Nguyen MTN, Verhelst SHL, et al: General and modular strategy for designing potent, selective, and pharmacologically compliant inhibitors of rhomboid proteases. Cell Chem Biol. 24:1523–1536.e4. 2017.PubMed/NCBI View Article : Google Scholar

53 

Aljohny BO, Rauf A, Anwar Y, Naz S and Wadood A: Antibacterial, antifungal, antioxidant, and docking studies of potential dinaphthodiospyrols from Diospyros lotus Linn roots. ACS Omega. 6:5878–5885. 2021.PubMed/NCBI View Article : Google Scholar

54 

Jia CY, Li JY, Hao GF and Yang GF: A drug-likeness toolbox facilitates ADMET study in drug discovery. Drug Discov Today. 25:248–258. 2020.PubMed/NCBI View Article : Google Scholar

55 

Ononamadu C and Ibrahim A: Molecular docking and prediction of ADME/drug-likeness properties of potentially active antidiabetic compounds isolated from aqueous-methanol extracts of Gymnema sylvestre and Combretum micranthum. B BioTechnologia (Pozn). 102:85–99. 2021.PubMed/NCBI View Article : Google Scholar

56 

Bickerton GR, Paolini GV, Besnard J, Muresan S and Hopkins AL: Quantifying the chemical beauty of drugs. Nat Chem. 4:90–98. 2012.PubMed/NCBI View Article : Google Scholar

57 

Sympli HD: Estimation of drug-likeness properties of GC-MS separated bioactive compounds in rare medicinal Pleione maculata using molecular docking technique and SwissADME in silico tools. Netw Model Anal Health Inform Bioinform. 10(14)2021.PubMed/NCBI View Article : Google Scholar

58 

Protti ÍF, Rodrigues DR, Fonseca SK, Alves RJ, de Oliveira RB and Maltarollo VG: Do drug-likeness rules apply to oral prodrugs? ChemMedChem. 16:1446–1456. 2021.PubMed/NCBI View Article : Google Scholar

59 

Ursu O, Rayan A, Goldblum A and Oprea TI: Understanding drug-likeness. WIREs Comput Mol Sci. 1:760–781. 2011.

60 

Alghamdi AA, ALAM M and Nazreen S: In silico ADME predictions and in vitro antibacterial evaluation of 2-hydroxy benzothiazole-based 1,3,4-oxadiazole derivatives. Turk J Chem. 44:1068–1084. 2020.PubMed/NCBI View Article : Google Scholar

61 

Okolo EN, Ugwu DI, Ezema BE, Ndefo JC, Eze FU, Ezema CG, Ezugwu JA and Ujam OT: New chalcone derivatives as potential antimicrobial and antioxidant agent. Sci Rep. 11(21781)2021.PubMed/NCBI View Article : Google Scholar

62 

Aliye M, Dekebo A, Tesso H, Abdo T, Eswaramoorthy R and Melaku Y: Molecular docking analysis and evaluation of the antibacterial and antioxidant activities of the constituents of Ocimum cufodontii. Sci Rep. 11(10101)2021.PubMed/NCBI View Article : Google Scholar

63 

Ballante F: Protein-ligand docking in drug design: Performance assessment and binding-pose selection. Methods Mol Biol. 1824:67–88. 2018.PubMed/NCBI View Article : Google Scholar

64 

Abishad P, Niveditha P, Unni V, Vergis J, Kurkure NV, Chaudhari S, Rawool DB and Barbuddhe SB: In silico molecular docking and in vitro antimicrobial efficacy of phytochemicals against multi-drug-resistant enteroaggregative Escherichia coli and non-typhoidal Salmonella spp. Gut Pathog. 13(46)2021.PubMed/NCBI View Article : Google Scholar

65 

Yao X, Hu H, Wang S, Zhao W, Song M and Zhou Q: Synthesis, antimicrobial activity, and molecular docking studies of aminoguanidine derivatives containing an acylhydrazone moiety. Iran J Pharm Res. 20(536)2021.PubMed/NCBI View Article : Google Scholar

66 

Saqallah FG, Hamed WM, Talib WH, Dianita R and Wahab HA: Antimicrobial activity and molecular docking screening of bioactive components of Antirrhinum majus (snapdragon) aerial parts. Heliyon. 8(e10391)2022.PubMed/NCBI View Article : Google Scholar

67 

Kumutanat W, Hongthong S, Thanasansurapong S, Kongkum N and Chumnanvej N: GC-MS and bioassay-guided isolation of xanthones from Mammea siamensis. Indones J Chem. 23(716)2023.

68 

Ye X, Lu J and Cao L: GC-MS analysis of volatile components extracted from fruit of Artemisia argyi. Med Plant. 8:10–13. 2017.

69 

Radzhabov GK, Aliev AM, Musaev AM and Islamova FI: Variability of the constituent composition of Achillea millefolium essential oils in the wild flora of Dagestan. Pharm Chem J. 56:661–666. 2022.

70 

Jasaitytė J, Kubilienė L, Stankevičius M and Maruška AS: Determination of propolis volatile compounds by GC-MS method. The vital nature sign [elektroninis išteklius]: 8th International scientific conference: Abstract book. Kaunas: Vytautas Magnus University, 8, 2014. https://www.vdu.lt/cris/entities/publication/797d1f5f-212f-4d6c-8f01-3c6b474c13d6.

71 

Carrillo-Morales M, Wong-Villarreal A, Aguilar-Marcelino L, Castañeda-Ramírez GS, Antonio Pineda-Alegría J and Hernández-Núñez E: Chemical composition and antifungal and nematicidal activities of the hexanic and methanolic extracts of Syzygium aromaticum. ScienceAsia. 49:124–130. 2023.

72 

Lin F and Long C: GC-TOF-MS-based metabolomics correlated with bioactivity assays unveiled seasonal variations in leaf essential oils of two species in Garcinia L. Ind Crops Prod. 194(116356)2023.

73 

Šudomová M, Hassan STS, Khan H, Rasekhian M and Nabavi SM: A multi-biochemical and in silico study on anti-enzymatic actions of pyroglutamic acid against PDE-5, ACE, and urease using various analytical techniques: Unexplored pharmacological properties and cytotoxicity evaluation. Biomolecules. 9(392)2019.PubMed/NCBI View Article : Google Scholar

74 

Samarakoon S: Phosphodiesterase-5 (PDE5) inhibitory potential of major phytochemicals of withania somnifera and cardiospermum halicacabum: An in silico comparison with approved PDE5 inhibitors. Authorea Preprints, 2023.

75 

Anyubaga SB, Shallangwa GA, Uzairu A and Abechi SE: Chemo-informatics applications in the design of novel 7-keto-sempervirol derivatives as SmCB1 inhibitors with potential for treatment of Schistosomiasis. Heliyon. 10(e23115)2023.PubMed/NCBI View Article : Google Scholar

76 

Kačániová M, Galovičová L, Borotová P, Valková V, Ďúranová H, Kowalczewski PŁ, Said-Al Ahl HAH, Hikal WM, Vukic M, Savitskaya T, et al: Chemical composition, in vitro and in situ antimicrobial and antibiofilm activities of Syzygium aromaticum (Clove) essential oil. Plants (Basel). 10(2185)2021.PubMed/NCBI View Article : Google Scholar

77 

Coleman RG, Carchia M, Sterling T, Irwin JJ and Shoichet BK: Ligand pose and orientational sampling in molecular docking. PLoS One. 8(e75992)2013.PubMed/NCBI View Article : Google Scholar

78 

Peach ML and Nicklaus MC: Combining docking with pharmacophore filtering for improved virtual screening. J Cheminform. 1(6)2009.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

October-2024
Volume 21 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wahyuni DK, Junairiah J, Rosyanti C, Kharisma VD, Syukriya AJ, Rahmawati CT, Purkan P, Subramaniam S, Prasongsuk S, Purnobasuki H, Purnobasuki H, et al: Computational and <em>in vitro</em> analyses of the antibacterial effect of the ethanolic extract of <em>Pluchea indica</em> L. leaves. Biomed Rep 21: 137, 2024.
APA
Wahyuni, D.K., Junairiah, J., Rosyanti, C., Kharisma, V.D., Syukriya, A.J., Rahmawati, C.T. ... Purnobasuki, H. (2024). Computational and <em>in vitro</em> analyses of the antibacterial effect of the ethanolic extract of <em>Pluchea indica</em> L. leaves. Biomedical Reports, 21, 137. https://doi.org/10.3892/br.2024.1825
MLA
Wahyuni, D. K., Junairiah, J., Rosyanti, C., Kharisma, V. D., Syukriya, A. J., Rahmawati, C. T., Purkan, P., Subramaniam, S., Prasongsuk, S., Purnobasuki, H."Computational and <em>in vitro</em> analyses of the antibacterial effect of the ethanolic extract of <em>Pluchea indica</em> L. leaves". Biomedical Reports 21.4 (2024): 137.
Chicago
Wahyuni, D. K., Junairiah, J., Rosyanti, C., Kharisma, V. D., Syukriya, A. J., Rahmawati, C. T., Purkan, P., Subramaniam, S., Prasongsuk, S., Purnobasuki, H."Computational and <em>in vitro</em> analyses of the antibacterial effect of the ethanolic extract of <em>Pluchea indica</em> L. leaves". Biomedical Reports 21, no. 4 (2024): 137. https://doi.org/10.3892/br.2024.1825